Breast Cancer Coverage from Every Angle

Sara A. Hurvitz, MD, on Outcomes for Different Racial Groups Treated With Talazoparib for Breast Cancer

Posted: Tuesday, April 21, 2020

Sara A. Hurvitz, MD, of the University of California, Los Angeles, discusses the self-reported outcomes of women from different racial groups with HER2-negative locally advanced or metastatic breast cancer and a germline BRCA1/2 mutation who were treated with the PARP inhibitor talazoparib vs chemotherapy in the EMBRACA trial.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.